These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18372907)

  • 1. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies.
    Siegal D; Xu W; Sutherland R; Kamel-Reid S; Kuruvilla J; Lipton JH; Minden M; Messner H; Gupta V
    Bone Marrow Transplant; 2008 Jul; 42(1):51-6. PubMed ID: 18372907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
    Gupta V; Ball SE; Sage D; Ortin M; Freires M; Gordon-Smith EC; Marsh JC
    Bone Marrow Transplant; 2005 Mar; 35(5):467-71. PubMed ID: 15665848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
    Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
    Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation.
    Arranz R; Conde E; Rodriguez-Salvanés F; Pajuelo FJ; Cabrera R; Sanz MA; Petit J; Bueno J; Maldonado J; Odriozola J; Conde JG; Brunet S; Carreras E; Iriondo A; Fernández-Rañada JM; Marín P;
    Bone Marrow Transplant; 2002 Feb; 29(3):205-11. PubMed ID: 11859392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
    Rzepecki P; Sarosiek T; Szczylik C
    Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
    Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Favorable current prognosis after HLA-identical bone marrow transplantation for children with required severe aplastic anemia; evaluation of 30 years of bone marrow transplantation at the Leiden University Medical Center].
    van Steekelenburg M; van Weel-Sipman MH; Zwinderman AH; Hoogerbrugge PM; Vossen JM; Egeler RM
    Ned Tijdschr Geneeskd; 2002 Aug; 146(33):1542-6. PubMed ID: 12212502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Yang DH; Lee JJ; Kim YK; Kim HJ; Shin HJ; Chung JS; Cho GJ
    Am J Hematol; 2008 Aug; 83(8):649-53. PubMed ID: 18528826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporin A in marrow transplantation for leukemia and aplastic anemia.
    Bacigalupo A; Frassoni F; van Lint MT; Raffo MR; Vitale V; Corbetta G; Chierichetti S; Marmont AM
    Exp Hematol; 1985 May; 13(4):244-8. PubMed ID: 3886417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Audit of peripheral stem cell transplantation for aplastic anemia in multitransfused infected patients.
    Seth T; Kanga U; Sood P; Sharma V; Mishra P; Mahapatra M
    Transplant Proc; 2012 May; 44(4):922-4. PubMed ID: 22564586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective.
    Schub N; Günther A; Schrauder A; Claviez A; Ehlert C; Gramatzki M; Repp R
    Bone Marrow Transplant; 2011 Jan; 46(1):143-7. PubMed ID: 20348971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.
    Jacobs P; Wood L; Fullard L; Waldmann H; Hale G
    Bone Marrow Transplant; 1994 Jun; 13(6):763-9. PubMed ID: 7920312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.